Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapaquistat acetate 50 mg vs placebo in hypercholesterolemia
2007-001489-34Phase 3Terminated
- Sponsor
- Takeda
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and lipid disorder comparing Lapaquistat acetate 50 mg QD with Placebo QD (2 arms). Primary endpoint: Change in LDL-C. Started May 2007; status: terminated.
02
Drugs
lapaquistat
03
Conditions
hypercholesterolemialipid disorder
Beyond the preview
Go deeper on 2007-001489-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001489-34.